Pharma/Vaccine Exec Brad Thompson Joins Fuld & Company as Advisory Board Member

 Fuld & Company, a fast-growing research, analytics, and advisory business, today announced the appointment of Brad Thompson to the role of Advisory Board Member. In this role, Brad will advise Fuld’s teams and clients from the Health and Life Sciences industries, and support their portfolio of solutions, including market and business research, competitive intelligence, thought leadership, data analytics, strategic insights, and shared services.

Brad is a well-known commercial leader and influencer in the pharmaceuticals industry, especially in the fields of Infectious diseases, Immunology, and Vaccines. During his tenure at top pharmaceutical firms such as Pfizer and Merck, Brad was an integral part of the commercial introduction of blockbuster brands. He is a results-oriented leader with a strong track record of developing franchise and brand strategies, as well as building marketing and sales teams in the pharmaceutical industry to optimize new and challenging opportunities.

Based in Philadelphia, PA, Brad holds an MBA from the Fairleigh Dickinson University and a BA in Economics from University of Pittsburgh.

“Joining Fuld & Company is an exciting opportunity for me to work with global leaders in research, analytics, and intelligence,” says Brad. “During the past 20+ years, I have contributed to the launch of several crucial pharmaceutical brands resulting in millions of saved lives. I plan to leverage that experience to help Fuld’s biotech and pharma clients successfully bring their own products to market. I’m eager to work with the talented team of consultants and researchers at Fuld to help these companies develop the right products and reach the patients that need them most.”

Alok Tayal, Chairman of Fuld & Company adds, “Fuld is growing rapidly, and our success is driven by our ability to provide sector-specialized services that contribute to our clients’ revenue growth. In addition, it helps our clients compete better in the marketplace, develop new markets, connect effectively with their customers and uplift their margins. Brad’s passion for healthcare, his experience with the world’s foremost pharmaceutical companies, and his deep industry knowledge, make him an ideal Advisory Board member to help propel our clients’ success.”

About Fuld & Company

Fuld & Company is a competitive strategy consultancy that helps clients anticipate competitive activity, see beyond market disruptions and develop or refine robust business strategies. Through research and evidence-based analysis, Fuld & Company delivers sound expertise to solve complex and tactical challenges for its Global Fortune 1,000 clients. Fuld & Company has been a pioneer in competitive strategy consulting for over 40 years, and its leaders have been recognized by top-tiered publications such as Fortune, Harvard Business Review & Fast Company.

Fuld & Company

Elaine Pratt


Chief Marketing Officer



  • Business
  • Medical & Health
  • Personnel Announcements
  • Pharmaceuticals

AIM Vaccine, a Major Player in the Chinese Vaccine Industry Successfully Listed on the Main Board of SEHK

AIM Vaccine Co., Ltd. (“AIM Vaccine” or the “Company”, together with its subsidiaries, the “Group”, stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today, with a board lot of 200 H shares each. The debut of AIM Vaccine’s stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%.

Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited and Macquarie Capital Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCI Asia Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the Joint Bookrunners and Joint Lead Managers. ICBC International Capital Limited is Joint Bookrunner, ICBC International Securities Limited and Livermore Holdings Limited are the Joint Lead Managers.

The Company said that the listing of AIM Vaccine in Hong Kong marks a key milestone and unfolds a new chapter in the Company’s development. Looking ahead, AIM Vaccine will continue to strive to access to quality industry resources to expand and optimize its business. The Company will keep abreast of the most advanced platform technologies and innovation trends, accelerating the development of vaccine candidates and continuing to enrich its product portfolio, solidifying and expanding market leadership by increasing sales and marketing efforts for approved vaccine products and commercializing new products, thereby realizing its mission to “develop and manufacture top quality vaccines to safeguard the health of the world”, becoming a world-class vaccine company in the global vaccine market and creating greater value for shareholders.

Topic: Press release summary

Sectors: BioTech, Healthcare & Pharm

From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Amidst Vaccine Hesitancy, Psychologist Offers Solutions to Overcome the Fear of Needles in His New Book

 “I’m scared to death of needles!” It’s a common complaint often joked about. But a needle phobia, known as trypanophobia, can have life-threatening side effects. In “Conquer Needle Phobia,” Dr. Marty Martin provides science-based solutions to help those that suffer from this phobia overcome the fear and experience the freedom that comes with taking back control of their medical care. At a time when the COVID-19 vaccine is becoming more essential, this advice could prove lifesaving.

“How do I know if I have just a healthy fear of needles or an actual phobia?” Martin begins here, helping readers understand their fears and what techniques are available to help them. He organized “Conquer Needle Phobia” to be a toolkit that readers can keep with them to prepare and make it through a medical appointment that involves needles. This includes step-by-step instructions for employing techniques like self-talk, distraction, exposure therapy, and mindfulness. With such practical advice, the book can be used both by individuals and by health care professionals to better navigate needle phobia in patients.

Available as both a Kindle eBook and paperback on Amazon, “Conquer Needle Phobia” was released on August 18, 2021, and is distributed by Bublish, Inc.

About the Author

Not only is Dr. Marty Martin an accomplished Clinical Health Psychologist specializing in phobias and sleep disorders, but he also knows first-hand the terror injections and needles can cause. For years he suffered from the phobia, avoiding medical appointments and procrastinating on visits to the dentist. Martin used the techniques he now teaches others to now fully-tolerate injections and blood draws.

Martin’s work has been recognized by USA Today, The Washington Post and numerous other media. His passion comes from translating his clinical and academic work as a Full Professor at DePaul University into useful training and teaching for practical applications. As the need becomes more pressing, Martin hopes to scale his advice for overcoming needle phobia into a mobile app for use by patients during their doctor’s appointments, dental appointments, or vaccine visits.

Learn more about Dr. Marty Martin at Find out more about Bublish, Inc. and its services at


Kathy Meis


Dr. Marty Martin




  • Books
  • Emergency Medicine
  • Infectious Diseases
  • Medical & Health
  • Mental Health